Open Access iconOpen Access

REVIEW

crossmark

Tumor neoantigens: Novel strategies for application of cancer immunotherapy

HANYANG GUAN1,#, YUE WU2,#, LU LI3,#, YABING YANG1, SHENGHUI QIU1, ZHAN ZHAO1, XIAODONG CHU1, JIASHUAI HE1, ZUYANG CHEN1, YIRAN ZHANG1, HUI DING1, JINGHUA PAN1,*, YUNLONG PAN1,*

1 Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China
2 Department of Gynecology, Women’s Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, 210004, China
3 Department of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China

* Corresponding Authors: JINGHUA PAN. Email: email; YUNLONG PAN. Email: email
# These authors contributed equally to this work

Oncology Research 2023, 31(4), 437-448. https://doi.org/10.32604/or.2023.029924

Abstract

Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for treating cancer. The recognition of antigens by immune cells is a crucial step in tumor-specific killing, and neoantigens generated by mutations in cancer cells possess high immunogenicity and are selectively expressed in tumor cells, making them an attractive therapeutic target. Currently, neoantigens find utility in various domains, primarily in the realm of neoantigen vaccines such as DC vaccines, nucleic acid vaccines, and synthetic long peptide vaccines. Additionally, they hold promise in adoptive cell therapy, encompassing tumor-infiltrating cells, T cell receptors, and chimeric antigen receptors which are expressed by genetically modified T cells. In this review, we summarized recent progress in the clinical use of tumor vaccines and adoptive cell therapy targeting neoantigens, discussed the potential of neoantigen burden as an immune checkpoint in clinical settings. With the aid of state-of-the-art sequencing and bioinformatics technologies, together with significant advancements in artificial intelligence, we anticipated that neoantigens will be fully exploited for personalized tumor immunotherapy, from screening to clinical application.

Graphical Abstract

Tumor neoantigens: Novel strategies for application of cancer immunotherapy

Keywords


Cite This Article

APA Style
GUAN, H., WU, Y., LI, L., YANG, Y., QIU, S. et al. (2023). Tumor neoantigens: novel strategies for application of cancer immunotherapy. Oncology Research, 31(4), 437-448. https://doi.org/10.32604/or.2023.029924
Vancouver Style
GUAN H, WU Y, LI L, YANG Y, QIU S, ZHAO Z, et al. Tumor neoantigens: novel strategies for application of cancer immunotherapy. Oncol Res. 2023;31(4):437-448 https://doi.org/10.32604/or.2023.029924
IEEE Style
H. GUAN et al., "Tumor neoantigens: Novel strategies for application of cancer immunotherapy," Oncol. Res., vol. 31, no. 4, pp. 437-448. 2023. https://doi.org/10.32604/or.2023.029924



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1396

    View

  • 520

    Download

  • 1

    Like

Share Link